Rifampicin treatment greatly increases the apparent oral clearance of quinidine

Pharmacology and Toxicology

Volumn 85, Issue 6, 1999, Pages 257-262

  Damkier, Per ^a   Hansen, Lone L ^a   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

QUINIDINE; QUINIDINE SULFATE; RIFAMPICIN; TOLBUTAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; URINALYSIS;

EID: 0033452495     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb02019.x     Document Type: Article

References (38)

1. Bachmann, K. A. & L. Jauregui: Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993, 23, 307-315.
2. Backman, J. T., K. T. Kivistö, K. T. Olkkola & P. J. Neuvonen: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 1998, 54, 53-58.
3. Backman, J. T., K. T. Olkkola & P. J. Neuvonen: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Therap. 1996, 59, 7-13.
4. Eichelbaum, M., S. Mineshita, E. E. Ohnhaus & C. Zekorn: The influence of enzyme induction on polymorphic sparteine oxidation. Brit. J. Clin. Pharmacol. 1986, 22, 49-53.
5. Emi, Y., D. Tsunashima, K. Ogawara, K. Higaki, & T. Kimura: Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J. Pharm. Sci. 1998, 87, 295-299.
6. Feng, H. J., S. L. Huang, W Wang & H. H. Zhou: The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to Ml mutation of CYP2C19 and gene dose. Brit. J. Clin. Pharmacol. 1998, 45, 27-29.
7. Frye, R. F., G. R. Matzke, A. Adedoyin, J. A. Porter, & R. A. Branch: Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Therap. 1997, 62, 365-376.
8. Fuhr, U., K. L. Rost, R. Engelhardt, M. Sachs, D. Liermann, C. Belloc, P. Beaune, S. Janezic, D. Grant, U. A. Meyer & A. H. Staib: Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996, 6, 159-176.
9. Ged, C., J. M. Rouillon, L. Pichard, J. Combalbert, N. Bressot, P. Bories, H. Michel, P. Beaune & P. Maurel: The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Brit. J. Clin. Pharmacol 1989, 28, 373-387.
10. Gillum, J. G., J. M. Sesler, V. L. Bruzzese, D. S. Israel & R. E. Polk: Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. Antimicrob. Agents Chemother. 1996, 40, 1866-1869.
11. Guengerich, F. P., D. Muller Enoch & I. A. Blair: Oxidation of quinidine by human liver cytochrome P-450. Mal. Pharmacol. 1986, 30, 287-295.
12. Hansen, L. L. & K. Brøsen: Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection. Ther. Drug Monit. 1999, in press.
13. Hebert, M.F., J. P. Roberts, T. Prueksaritanont & L. Z. Benet: Bio-availability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Therap. 1992, 52, 453-457.
14. Holtbecker, N., M. F. Fromm, H. K. Kroemer, E. E. Ohnhaus & H. Heidemann: The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab. Disp. 1996, 24, 1121-1123.
15. Kivistö, K. T. & H. K. Kroemer: Use of probe drugs as predictors of drug metabolism in humans. J. Clin. Pharmacol. 1997, 37, 40-48.
16. Kolars, J. C., P. Schmiedlin Ren, J. D. Schuetz, C. Fang & P B. Watkins: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 1992, 90, 1871-1878.
17. Kusuhara, H., H. Suzuki, T. Terasaki, A. Kakee, M. Lemaire & Y. Sugiyama: P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J. Pharmacol. Exp. Therap. 1997, 283, 574-580.
18. Lykkesfeldt, J., S. Loft & H. E. Poulsen: Simultaneous determination of urinary free cortisol and 6 beta- hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J. Chromatogr. B. Biomed. Appl. 1994, 660, 23-29.
19. Ndanusa, B. U., A. Mustapha & A. I. Abdu: The effect of single dose of rifampicin on the pharmacokinetics of oral nifedipine. J. Pharm. Biomed. Anal. 1997, 15, 1571-1575.
20. Nielsen, F., K. K. Nielsen & K. Brosen: Determination of quinidine, dihydroquinidine, (3S)-3- hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 1994, 660, 103-110.
21. Nielsen, T. L., B. B. Rasmussen, J.-P. Flinois, P. Beaune & K. Brøsen: In vitro metabolism of quinidine: the (3S)-3-hydroxylation is a specific marker reaction for cytochrome P4503A4 activity in human liver microsomes. J. Pharmacol. Exp. Therap. 1999, 289, 31-37.
22. Rasmussen, B. B. & K. Brøsen: Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br. J. Clin. Pharmacol. 1997, 43, 253-258.
23. Robson, R. A., J. O. Miners, L. H. Wing & D. J. Birkett: Theophylline-rifampicin interaction: Non-selective induction of theophylline metabolic pathways. Brit. J. Clin. Pharmacol. 1984, 18, 445-448.
24. Sanz, E. J., T. Villen, C. Alm & L. Bertilsson: S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin. Pharmacol Therap. 1989, 45, 495-499.
25. Schuetz, E. G., W. T. Beck & J. D. Schuetz: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 1996, 49, 311-318.
26. Shimada, H., T. Yamazaki, M. Mimura, Y. Inui & F. P. Guengerich: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharm. Exp. Therap. 1994, 270, 414-423.
27. Soto, J., J. A. Sacristan & M. J. Alsar: Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism. Ann. Pharmacother. 1996, 30, 736-739.
28. Twum Barima, Y. & S. G. Carruthers: Quinidine-rifampin interaction. N. Engl. J. Med. 1981, 304, 1466-1469.
29. Veronese, M. E., J. O. Miners, D. Randles, D. Gregov & D. J. Birkett: Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin. Pharmacol. Therap. 1990, 47, 403-411.
30. Vinks, A., T. Inaba, S. V. Otton & W. Kalow: Sparteine metabolism in Canadian Caucasians. Clin. Pharmacol. Therap. 1982, 31, 23-29.
31. Wacher, V. J., C. Y. Wu & L. Z. Benet: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 1995, 13, 129-134.
32. Watkins, P. B.: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994, 4, 171-184.
33. Watkins, P. B., S. A. Murray, L. G. Winkelman, D. M. Heuman, S. A. Wrighton & P. S. Guzelian: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest. 1989, 83, 688-697.
34. Wietholtz, H., T. Zysset, H. U. Marschall, K. Generet & S. Matern: The influence of rifampin treatment on caffeine clearance in healthy man. J. Hepatol. 1995, 22, 78-81.
35. Wu, C. Y., L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez & V. J. Wacher: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Therap. 1995, 58, 492-497.
36. Zhou, H. H., L. B. Anthony, A. J. Wood & G. R. Wilkinson: Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Brit. J. Clin. Pharmacol. 1990, 30, 471-475.
37. Zilly, W., D. D. Breimer & E. Richter: Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 1975, 9, 219-227.
38. Zilly, W, D. D. Breimer & E. Richter: Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 1977, 11, 287-293.